Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
NCT ID: NCT01062438
Last Updated: 2015-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
99 participants
OBSERVATIONAL
2010-01-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at DNA in tumor tissue samples from patients with localized or metastatic osteosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01190943
DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers
NCT01139983
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01807143
DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma
NCT01419509
Study of Blood Samples From Patients With Osteosarcoma
NCT00954473
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the genomic expression profile in tumor tissue samples from patients with localized or metastatic osteosarcoma using transcriptome sequencing.
* Identify activating and loss of function mutations and gene rearrangement in these tumor tissue samples using transcriptome sequencing.
* Identify candidate genes that are important in osteosarcoma and tumorigenesis using genome partition strategies for genomic DNA sequencing.
* Identify which mutations are associated with outcome.
* Establish which mutations are also found in germ line DNA that predispose the patient to osteosarcoma.
OUTLINE: DNA and RNA from banked tumor tissue samples and DNA from paired blood samples are analyzed in sequencing studies using next-generation sequencing technology. The sequencing data from these tumor samples are matched to the Human RefSeq (for transcriptome sequencing) and normal human genome in the public databases and to the patient's germ line sequence to identify constitutional and somatic mutations.
Clinical information that is associated with each sample (i.e., age, tumor site, size, primary metastases, response to chemotherapy, surgical remission, follow-up time, and treatment protocol) is also collected, if available.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
RNA analysis
gene expression analysis
gene rearrangement analysis
mutation analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of localized or metastatic osteosarcoma
* Banked snap-frozen tumor tissue samples and paired blood DNA samples available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Javed Khan, MD
Role: PRINCIPAL_INVESTIGATOR
NCI - Oncogenomics Section
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AOST10B3
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000665327
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02210
Identifier Type: REGISTRY
Identifier Source: secondary_id
AOST10B3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.